Proyectos de ley › 90.ª Asamblea General
Relating to insurance coverage for biomarker testing
Presentado por el comité Commerce de la Cámara
Dónde está ahora
- Hecho: Presentado25 de enero de 2024
- Hecho: Subcomité31 de enero de 2024
- Hecho: Comité de la Cámara8 de febrero de 2024
- Se saltó: Lo aprueba la CámaraSigue como HF 2668
- Sigue: Comité del Senado
- Sigue: Lo aprueba el Senado
- Sigue: A gobernador(a)
- Sigue: Firmado como ley
Ahora es HF 2668 → Sigue avanzando con el número nuevo. Ir a HF 2668 ¿Qué es el embudo (funnel)?
Qué cambió antes de aprobarse El proyecto tal como se presentó, comparado con la versión que aprobaron ambas cámaras.
Amendments · 5
2 adopted · 0 failed · 3 never voted on. Newest first.
- H-8294 · filed April 9, 2024 byNever voted onAI summary This amendment replaces the existing definition of "clinical utility" with a new definition. The new definition requires that there be enough medical and scientific evidence to show that a biomarker test provides useful information for making treatment decisions and improving health outcomes. Its wording →
- S-5124 · filed April 8, 2024 by Sen. Waylon Brown (R)AdoptedAI summary This amendment adds a specific definition for the term "clinical utility" to be used in the bill. It defines the term as having enough medical and scientific evidence to show that a biomarker test provides useful information for making treatment decisions and improving health outcomes. Its wording →April 9, 2024
- S-5123Strike everything · filed April 8, 2024 by Sen. Waylon Brown (R)AdoptedAI summary This amendment replaces the entire bill with a new version that requires certain insurance plans and state medical assistance programs to cover biomarker testing when it shows clinical utility. It defines specific terms like "biomarker" and "clinical utility" and lists specific types of coverage, such as FDA-approved tests or national clinical guidelines, that must be met. The amendment also requires insurance companies to provide an online process for requesting coverage exceptions and directs the Department of Health and Human Services to report on the number and cost of biomarker tests provided under state programs. Its wording →Amends this SF 2159 to CONFORM to HF 2668April 9, 2024
- H-8050 · filed February 26, 2024 byNever voted onAI summary This amendment changes the requirements for coverage by stating that biomarker tests must either show clinical utility or be considered medically necessary. It specifically clarifies that tests are medically necessary if the results help doctors create a treatment or monitoring plan that affects a patient's health outcome. Its wording →
- H-8022 · filed February 19, 2024 byNever voted onAI summary This amendment provides a specific definition for the term "clinical utility" regarding how test results are used to guide medical decisions. It also changes one word in the bill, replacing "costs" with "risks." Its wording →